Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-UK: Tocilizumab in Pulmonary Arterial Hypertension
2015-002799-26Phase 2Completed
- Sponsor
- Papworth Hospital NHS Foundation Trust
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in pulmonary arterial hypertension (PAH), sponsored by Papworth Hospital NHS Foundation Trust. Primary endpoint: Pulmonary arterial pressure reduction. Started Sep 2015; status: completed.
02
Drugs
tocilizumab
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2015-002799-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002799-26.